Cargando…

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia

Selective cytotoxicity to cancer cells without compromising their normal counterparts pose a huge challenge for traditional drug design. Here we developed a tumor antigen targeted delivery of immunonanoparticle carrying a novel non-immunosuppressive FTY720 derivative OSU-2S with potent cytotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mani, Rajeswaran, Mao, Yicheng, Frissora, Frank W., Chiang, Chi-Ling, Wang, Jiang, Zhao, Yuan, Wu, Yun, Yu, Bo, Yan, Ribai, Mo, Xiaokui, Yu, Lianbo, Flynn, Joseph, Jones, Jeffrey, Andritsos, Leslie, Baskar, Sivasubramanian, Rader, Christoph, Phelps, Mitch A, Chen, Ching-Shih, Lee, Robert J., Byrd, John C., Lee, L. James, Muthusamy, Natarajan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272672/ https://www.ncbi.nlm.nih.gov/pubmed/24947019 http://dx.doi.org/10.1038/leu.2014.199

Ejemplares similares

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model
por: Motiwala, Tasneem, et al.
Publicado: (2014)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
por: Beckwith, Kyle A., et al.
Publicado: (2014)

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
por: Yang, Jiahui, et al.
Publicado: (2011)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
por: Dave, Hema, et al.
Publicado: (2012)

CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway
por: Browning, Rebekah L., et al.
Publicado: (2015)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
por: Guinn, Daphne, et al.
Publicado: (2017)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
por: Gopalakrishnan, Bhavani, et al.
Publicado: (2018)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia
por: Cohen, Jonathon B., et al.
Publicado: (2012)

RORγt and RORα signature genes in human Th17 cells
por: Castro, Glenda, et al.
Publicado: (2017)

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
por: Yano, Max, et al.
Publicado: (2022)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

Tetraspanins as therapeutic targets in hematological malignancy: a concise review
por: Beckwith, Kyle A., et al.
Publicado: (2015)

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
por: Blum, Kristie A., et al.
Publicado: (2011)

RORα and RORγ expression inversely correlates with human melanoma progression
por: Brożyna, Anna A., et al.
Publicado: (2016)

New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
por: Raivola, Juuli, et al.
Publicado: (2022)

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C E, et al.
Publicado: (2016)

The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1
por: John, Miya, et al.
Publicado: (2022)

Fluorouracil Selectively Enriches Stem-like Leukemic Cells in a Leukemic Cell Line
por: Zhang, Ling, et al.
Publicado: (2010)

ROR: Nuclear Receptor for Melatonin or Not?
por: Ma, Haozhen, et al.
Publicado: (2021)

The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis
por: Ruan, Qingguo, et al.
Publicado: (2011)

Evolutionary Divergence in the Catalytic Activity of the CAM-1, ROR1 and ROR2 Kinase Domains
por: Bainbridge, Travis W., et al.
Publicado: (2014)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

The application of machine learning methods to the prediction of novel ligands for RORγ/RORγT receptors
por: Bachorz, Rafał A., et al.
Publicado: (2023)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

Prognostic Significance of ROR2 Expression in Patients with Urothelial Carcinoma
por: Yeh, Cheng-Fa, et al.
Publicado: (2021)

The roles of Linc-ROR in the regulation of cancer stem cells
por: Wen, Xiaoling, et al.
Publicado: (2022)

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
por: Chen, Timothy L., et al.
Publicado: (2016)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

Functional Variants in Linc-ROR are Associated with mRNA Expression of Linc-ROR and Breast Cancer Susceptibility
por: Luo, Chenglin, et al.
Publicado: (2018)

Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis
por: Henry, Claire, et al.
Publicado: (2017)

The role of mitochondrial proteases in leukemic cells and leukemic stem cells
por: Mirali, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e10iqeivmajgkp2n7s76ds19pu